WCLC 2026: Lung cancer research highlights
Published on 14 October 2026
Dr Luis Raez reviews four key lung cancer presentations from WCLC 2026, highlighting emerging antibody drug conjugates for small cell lung cancer, new targeted therapies for ROS1 positive NSCLC, and first line treatment developments for EGFR exon 20 insertion NSCLC.
| Tam-Peli, an anti-B7-H3 antibody-drug conjugate, versus topotecan in relapsed SCLC: A randomized, open-label, phase 3 study (TAISHAN-302) | |
| Risvutatug rezetecan (a B7-H3-Directed ADC) versus topotecan in relapsed SCLC: Primary results of phase 3 ARTEMIS-008 | |
| Zidesamtinib in TKI-naive patients with advanced/metastatic ROS1+ NSCLC: ARROS-1 efficacy and safety data | |
| Zipalertinib plus chemotherapy for 1st line NSCLC with EGFR exon 20 Insertions: Results from the phase 3 REZILIENT3 trial |